These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8996165)

  • 21. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
    Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
    Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The antiandrogen withdrawal syndrome.
    Wirth MP; Froschermaier SE
    Urol Res; 1997; 25 Suppl 2():S67-71. PubMed ID: 9144890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary hormonal therapies in the treatment of prostate cancer.
    OH WK
    Urology; 2002 Sep; 60(3 Suppl 1):87-92; discussion 93. PubMed ID: 12231058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nilutamide: possible utility as a second-line hormonal agent.
    Desai A; Stadler WM; Vogelzang NJ
    Urology; 2001 Dec; 58(6):1016-20. PubMed ID: 11744479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.
    Small EJ; Baron A; Bok R
    Cancer; 1997 Nov; 80(9):1755-9. PubMed ID: 9351544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The antiandrogen withdrawal syndrome: decrease in prostate specific antigen serum levels after withdrawal of antiandrogens].
    Hornák M; Bárdos A; Goncalves F
    Rozhl Chir; 1997 Sep; 76(9):435-7. PubMed ID: 9471771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormonal therapy of prostate cancer.
    Labrie F
    Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
    Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T
    Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer, Incidence, management and outcomes.
    Small EJ
    Drugs Aging; 1998 Jul; 13(1):71-81. PubMed ID: 9679210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
    Klotz L; Drachenberg D; Singal R; Aprikian A; Fradet Y; Kebabdjian M; Zarenda M; Chin J
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):320-4. PubMed ID: 25179591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
    Kassouf W; Tanguay S; Aprikian AG
    J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy.
    Okihara K; Ukimura O; Kanemitsu N; Mizutani Y; Kawauchi A; Miki T;
    Int J Urol; 2007 Feb; 14(2):128-32. PubMed ID: 17302569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A; Di Silverio F
    Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of antiandrogen therapy for treating prostate cancer.
    Ricci F; Buzzatti G; Rubagotti A; Boccardo F
    Expert Opin Drug Saf; 2014 Nov; 13(11):1483-99. PubMed ID: 25270521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The utility of prostate-specific antigen in the management of advanced prostate cancer.
    Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
    BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 39. Secondary hormonal therapy for advanced prostate cancer.
    Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
    J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
    Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
    Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.